Day: January 5, 2022

AllGo App Store provides an app-as-a-service solution that benefits content providers, automakers and consumers End-to-end infotainment solution integrates effortlessly with pre-loaded, optimized automotive-related apps Verified, trusted applications for OEMs, consumers and developersLAS VEGAS, Jan. 05, 2022 (GLOBE NEWSWIRE) — Visteon (NASDAQ: VC), a leading global technology company serving the mobility industry, today unveiled its AllGo App Store at CES® 2022 as one of the latest solutions in its growing portfolio of connected car technologies for the mobility industry. The AllGo App Store is designed to meet the growing global demand for safe and convenient ways to access app-based content in a smart, connected cockpit. It features automotive-optimized versions of the most sought-after mobility, navigation, parking and infotainment...

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, being held January 10-13, 2022. The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, January 10, 2022, in the Investors section on the Company’s website at www.traconpharma.com. About TRACON TRACON develops targeted therapies for cancer utilizing...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 11, 2021 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021. GATINEAU, Quebec, Jan. 05, 2022 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NASDAQ: HEXO), today announced the appointment of William Todd Montour to the Company’s Board of Directors following the resignation of Jason Ewart, effective immediately. “I am pleased to welcome Will to the Board, and I am confident that his experience in cannabis operations and commercialization will be invaluable to the Company as we enter our next stage of growth,” said John K. Bell, Chair of the Board of Directors, HEXO. “On behalf of HEXO’s...

Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22 Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track for interim results in 2Q22 and topline results in 4Q22Dosed first 10 patients in NSCLC trial; on track to conduct blinded safety evaluation on these patients after one cycle in 1Q22In 2021, Aileron was issued 7 new international patents, including new patent protection for ALRN-6924 in China, and 4 U.S. patents, adding to its strong intellectual property portfolio comprising over 170 U.S. and foreign patents and exclusive worldwide rights to ALRN-6924BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires...

PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30 a.m. ET. The presentation will be webcast live and can be accessed in the investor relations section of the Agile Therapeutics website here. About Agile Therapeutics, Inc.Agile Therapeutics is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol)...

Company announces several key U.S. Focal One installations during Q4 LYON, France, January 5, 2022 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent Focal One placements and the initiation of treatments at select new customer sites in the US. During the company’s third quarter 2021 conference call in November, EDAP announced that it had sold a Focal One device to the University of California at San Diego (UCSD) during the fourth quarter. The sale to UCSD is now the third Focal One placement into the prestigious UC healthcare system, following previously announced sales to UC San Francisco and UC Irvine. In addition, the company is today announcing that additional Focal One installations have occurred during the fourth quarter to five prestigious academic...

– Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases – SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research and development, including at two of the most prominent vaccine companies in the world, Sanofi Pasteur and Merck & Co., Inc. He has guided scientific teams to create novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including RSV, influenza, pneumococcus,...

Presentation at J.P. Morgan Healthcare Conference on January 13th Corporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10th Company to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rdJENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several investor events. 40th Annual J.P. Morgan Healthcare Conference: Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will give a corporate presentation on Thursday, January 13th at 11:15 am EST (5:15 pm CET) followed by a 20-minute Q&A. A live audio webcast and replay of the presentation will be provided...